Objective: How CRP activates Fc␥RIIB in endothelium is not known. We determined the role of Fc␥ receptor I (Fc␥RI) and the basis for coupling of Fc␥RI to Fc␥RIIB in endothelium. Key Words: C-reactive protein Ⅲ endothelial nitric oxide synthase Ⅲ Fc receptor C -reactive protein (CRP) is an acute phase reactant and a predictor of increased risk for cardiovascular disorders, including myocardial infarction, sudden cardiac death, stroke, peripheral vascular disease, and hypertension. 1-3 Studies in cell culture and in mice indicate that CRP antagonizes endothelial nitric oxide synthase (eNOS), resulting in the inhibition of endothelial cell migration, the promotion of endothelial cell-monocyte adhesion, impaired vascular wound repair, impaired vasorelaxation, and hypertension. 4 -6 CRP and immune complexes bind to cell plasma membranes via IgG Fc␥ receptors (Fc␥Rs). [7] [8] [9] We previously demonstrated that not only CRP but also immune complexes potently antagonize eNOS in cultured endothelial cells. 4 Fc␥R are categorized into activation receptors such as Fc␥RI, which contain a cytoplasmic immunoreceptor tyrosine-based activation motif located in its ␥-chain subunit (FcR␥), and inhibitory receptors such as Fc␥RIIB, which has an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. 9 We previously showed that CRP inhibition of eNOS requires Fc␥RIIB, the phosphorylation of its ITIM, and the resulting recruitment and activation of SH2 domaincontaining inositol 5Ј-phosphatase 1 (SHIP-1) via phosphorylation of Tyr1020. Activated SHIP-1 attenuates signaling downstream of PI3 kinase, blunting Akt activation and eNOS Ser1179 phosphorylation by Akt, thereby decreasing eNOS enzyme activation. 4,10 However, how CRP activates Fc␥RIIB is not known.
C
-reactive protein (CRP) is an acute phase reactant and a predictor of increased risk for cardiovascular disorders, including myocardial infarction, sudden cardiac death, stroke, peripheral vascular disease, and hypertension. [1] [2] [3] Studies in cell culture and in mice indicate that CRP antagonizes endothelial nitric oxide synthase (eNOS), resulting in the inhibition of endothelial cell migration, the promotion of endothelial cell-monocyte adhesion, impaired vascular wound repair, impaired vasorelaxation, and hypertension. 4 -6 CRP and immune complexes bind to cell plasma membranes via IgG Fc␥ receptors (Fc␥Rs). [7] [8] [9] We previously demonstrated that not only CRP but also immune complexes potently antagonize eNOS in cultured endothelial cells. 4 Fc␥R are categorized into activation receptors such as Fc␥RI, which contain a cytoplasmic immunoreceptor tyrosine-based activation motif located in its ␥-chain subunit (FcR␥), and inhibitory receptors such as Fc␥RIIB, which has an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. 9 We previously showed that CRP inhibition of eNOS requires Fc␥RIIB, the phosphorylation of its ITIM, and the resulting recruitment and activation of SH2 domaincontaining inositol 5Ј-phosphatase 1 (SHIP-1) via phosphorylation of Tyr1020. Activated SHIP-1 attenuates signaling downstream of PI3 kinase, blunting Akt activation and eNOS Ser1179 phosphorylation by Akt, thereby decreasing eNOS enzyme activation. 4, 10 However, how CRP activates Fc␥RIIB is not known.
To better understand the basis for CRP actions on endothelium, the present study was designed to delineate the mechanisms by which CRP activates Fc␥RIIB. In immune response cells such as lymphocytes, activating Fc␥R and inhibitory Fc␥R are frequently functionally coupled with the actions of activating Fc␥R opposing inhibitory Fc␥R function in some instances, and the actions of activating Fc␥R being required to initiate inhibitory Fc␥R function in others. 9, 11 Recognizing that Fc␥RI is coexpressed with Fc␥RIIB in endothelial cells, 4, 12 we raised the hypothesis that Fc␥RI is required for Fc␥RIIB-mediated actions of CRP on endothelium. In addition to testing this hypothesis, studies were performed to determine how Fc␥RI is coupled to Fc␥RIIB in endothelium. We also investigated whether immune complex-induced eNOS antagonism entails similar Fc␥RI-Fc␥RIIB functional linkage. Furthermore, to determine if these processes are operative in vivo, studies of carotid artery re-endothelialization were performed in mice derived from crosses of transgenic CRP mice (TG-CRP) with FcR␥ chainnull or Fc␥RIIB-null mice.
Methods

Cell Culture and Transfection
Using previously described approaches, primary bovine aortic endothelial cells (BAECs) were harvested, propagated, and used within nine passages. 10 In selected experiments, BAEC were transfected with cDNA encoding hemagglutanin-tagged human Fc␥RIIB as described previously. 10 In other experiments, primary aortic endothelial cells were harvested from Fc␥RI ϩ/ϩ and Fc␥RI Ϫ/Ϫ C57BL/6 mice. 13 Briefly, mouse thoracic aortas were removed, placed in DMEM with 20% fetal bovine serum and 1000 U/mL heparin, washed with DMEM, and filled with DMEM containing 2 mg/mL collagenase type II (Worthington) for 45 minutes at 37°C. Endothelial cells were then collected by flushing with 5 mL of DMEM with 20% fetal bovine serum, pelleted, and plated onto a 35-mm dish coated with collagen type I. After a 2-hour incubation, cells were washed twice with phosphate-buffered saline and placed in DMEM with 20% fetal bovine serum, penicillin-streptomycin, 2 mmol/L L-glutamine, 1ϫ nonessential amino acids, 1ϫ sodium pyruvate, 25 mmol/L HEPES, 100 g/mL heparin, and 100 g/mL endothelial cell growth supplement (Sigma-Aldrich). Mouse primary endothelial cells were used within three passages.
eNOS Activation Assays
eNOS activation was assessed in whole cells by measuring 14 C-Larginine conversion to 14 C-L-citrulline during 15-minute incubations as previously described. 5 eNOS agonists used were insulin (500 nmol/L) and acetylcholine (Ach; 10 mol/L). In select experiments, incubations were performed in the presence of human recombinant CRP (5 or 25 g/mL), heat-aggregated IgG (100 g/mL), PP2 (10 mol/L; Calbiochem, Gibbstown, NJ), piceatannol (10 mol/L; Calbiochem), anti-Fc␥RI antibodies (10 g/mL; anti-CD64, clones 10.1 and H-250; Santa Cruz Biotechnology, Santa Cruz, CA), or anti-FcRIII antibody (10 g/mL; anti-CD16, clone 3G8; Santa Cruz Biotechnology).
Immunoblot Analyses
Immunoblots were performed to assess Src kinase phosphorylation, Fc␥RIIB phosphorylation, and SHIP-1 phosphorylation. Antibodies used were anti-phospho-Src (Tyr416) (Cell Signaling Technology), anti-Src (Santa Cruz Biotechnology), antiphospho-Fc␥RIIB (Tyr292; Abcam), anti-Fc␥RIIB (Fitzgerald), antiphospho-SHIP-1 (Tyr1020; Cell Signaling Technology), and anti-SHIP-1 (Santa Cruz Biotechnology). Results shown were confirmed in three or more independent experiments.
Carotid Artery Re-Endothelialization
The care and use of all study animals were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center. Mice null for the FcR ␥-chain (FcR␥ Ϫ/Ϫ mice; C57BL/6; Taconic Farms, Hudson, NY) were crossed with CRP transgenic mice (TG-CRP; C57BL/6) expressing a transgene consisting of coding sequence for rabbit CRP linked to promoter and regulatory elements for the cytosolic form of rat PEPCK. 5 The progeny were crossed and experiments were performed in littermates in the resulting four groups of offspring: FcR␥ ϩ/ϩ , FcR␥ ϩ/ϩ ; TG-CRP, FcR␥ Ϫ/Ϫ , and FcR␥ Ϫ/Ϫ ; TG-CRP. Using an identical strategy with mating between TG-CRP and Fc␥RIIB Ϫ/Ϫ mice, littermates in the following four groups were also generated: Fc␥RIIB ϩ/ϩ , Fc␥RIIB ϩ/ϩ ; TG-CRP, Fc␥RIIB Ϫ/Ϫ , and Fc␥RIIB Ϫ/Ϫ ; TG-CRP. Carotid artery re-endothelialization after perivascular electric injury was studied in male mice at 11 to 13 weeks of age as previously described. 5, 14 Ninety-six hours after injury, the animals were injected with Evans blue dye, arteries were harvested, and the area of denudation that incorporated the dye was quantified by image analysis (FluorChem SP; AlphaEase FC software; Alpha Innotech) performed by an investigator blinded to group assignment. In a subset of mice, serum was obtained on the day of carotid artery denudation, and serum CRP levels were determined by enzyme-linked immunosorbent assay. 5, 15 CRP levels (meanϮSEM; nϭ5-6) in nontransgenic mice were Ͻ1 g/mL. In FcR␥ ϩ/ϩ ; TG-CRP and FcR␥ Ϫ/Ϫ ; TG-CRP littermates, they were 39Ϯ7 and 61Ϯ4 g/mL, respectively. In Fc␥RIIB ϩ/ϩ ; TG-CRP and Fc␥RIIB Ϫ/Ϫ ; TG-CRP littermates, they were 29Ϯ6 and 30Ϯ4 g/mL, respectively.
Statistical Analysis
Analysis of variance with Neuman-Keuls post hoc testing was used to assess differences between multiple groups, and significance was set at PϽ0.05. For an expanded Methods section, see the Online Supplement available at http://circres.ahajournals.org.
Results
CRP Antagonism of eNOS and Fc␥RI
To evaluate the potential role of Fc␥RI in endothelium in the actions of CRP, studies of eNOS activation by insulin were performed in BAEC ( Figure 1 ). Under control conditions, CRP (25 g/mL) caused an 82.7% decrease in eNOS activation by insulin, mirroring our previous findings. 4 In contrast, in cells treated with either of two Fc␥RI-blocking antibodies, 10.1 or H-250, CRP had no effect on eNOS activation. However, blocking antibody to Fc␥RIII did not alter CRP inhibition of eNOS activity. Thus, CRP antagonism of eNOS activation is Fc␥RI-dependent.
CRP Actions and Src Kinase
Knowing from previous work that CRP antagonism of eNOS is mediated by Fc␥RIIB, 4 and now having also implicated 9 we tested the requirement for these kinases in CRP inhibition of eNOS activity. In preliminary experiments we determined that eNOS activation by Ach in BAEC is Src-independent and Syk-independent (data not shown), making it feasible to use Ach as an agonist in studies of Src or Syk in CRP antagonism of eNOS. Ach increased eNOS activity, and this was fully inhibited by CRP as previously observed 4 ( Figure  2A ). However, CRP did not inhibit Ach-stimulated eNOS activity in the presence of the Src inhibitor PP2. In parallel experiments, the antagonism of Ach-induced eNOS activation by CRP was unaffected by the Syk inhibitor piceatannol ( Figure 2B ), which effectively prevented Syk activation by heat-aggregated IgG in Raji cells (data not shown).
To further interrogate the potential role of Src in CRP action in endothelial cells, we evaluated whether CRP activates Src by immunoblot analysis of Src phosphorylation at Tyr416. Using high-density lipoprotein as a positive control for Src stimulation in endothelial cells, 14, 16 we observed that within 10 minutes of CRP treatment (25 g/mL), Src phosphorylation was increased ( Figure 3A ). Heat-inactivated CRP (25 g/mL) did not stimulate Src phosphorylation (data not shown), indicating that the response requires the intact protein. Dose-response studies further revealed that Src activation occurs at CRP concentrations as low as 2 g/mL ( Figure 3B ), which is well within the range for modest chronic elevations in CRP that are associated with increased cardiovascular disease risk in humans, 17, 18 and which mirrors the dose-response for eNOS antagonism by CRP. 4 The role of Fc␥RI in CRP activation of Src was then interrogated in studies using primary mouse endothelial cells isolated from aortas of Fc␥RI ϩ/ϩ and Fc␥RI Ϫ/Ϫ mice. Figure 3C ).
To test the coupling of CRP-induced Fc␥RI-mediated Src activation to Fc␥RIIB, BAECs were transfected with cDNA encoding human Fc␥RIIB, and 48 hours later the phosphorylation of Fc␥RIIB Tyr292 in the ITIM domain in response to CRP was evaluated by immunoblot analysis. This approach was used because the abundance of endogenous Fc␥RIIB in BAECs was insufficient to detect changes in receptor phosphorylation (data not shown). CRP caused a robust increase in transfected Fc␥RIIB phosphorylation, and this was fully prevented by Src inhibition with PP2 ( Figure 4A ). The requirement for Src in the activation of SHIP-1 was tested in nontransfected BAECs. CRP activated SHIP-1 phosphorylation, and this was prevented by Src inhibition with PP2 ( Figure 4B ). These cumulative findings indicate that through Fc␥RI, CRP activates Src, leading to Fc␥RIIB ITIM phosphorylation and SHIP-1 recruitment and activation.
Basis of Immune Complex Action in Endothelium
We previously demonstrated that similar to the pentraxins CRP and SAP, heat-aggregated IgG used to mimic immune complex causes eNOS antagonism. 4 Although it has been shown that common Fc receptor-mediated processes underlie phagocytosis and cytokine secretion by leukocytes in response to pentraxins and immune complex, 19 it is unknown whether CRP and immune complex induce similar Fc␥R-mediated events in endothelial cells. Similar to CRP (Figure  2A ), heat-aggregated IgG used to mimic immune complex completely inhibited Ach-stimulated eNOS activity, and the suppression was fully reversed by PP2 antagonism of Src ( Figure 5A ). We further tested the effect of aggregated IgG on the phosphorylation of the ITIM of Fc␥RIIB in endothelial cells and found that similar to CRP (Figure 4A ), aggregated IgG stimulated Fc␥RIIB phosphorylation and the phosphorylation was prevented by PP2 ( Figure 5B ). Aggregated IgG also stimulated SHIP-1 phosphorylation in endothelial cells, 
C-reactive protein (CRP) stimulates Src through Fc␥ receptor I (Fc␥RI). A, Bovine aortic endothelial cells (BAECs)
were treated with CRP (25 g/mL) for 0 to 30 minutes and Src activation was analyzed by immunoblot analysis for phospho-Src (Tyr416) and total Src. High-density lipoprotein (50 g/mL) treatment for 10 minutes provided a positive control. Summary data for the ratio of pSrc to Src normalized to time 0 is provided. B, BAEC were treated with 0 to 25 g/mL CRP for 10 minutes, and Src activation was analyzed. Summary data for the ratio of pSrc to Src normalized to time 0 is provided. C, Mouse primary aortic endothelial cells from Fc␥RI ϩ/ϩ or Fc␥RI Ϫ/Ϫ mice were treated with high-density lipoprotein (50 g/mL) for 10 minutes or CRP (25 g/mL) for 15 minutes, and Src activation was analyzed. Summary data for the ratio of pSrc to Src normalized to basal is provided. Values are meanϮSEM, nϭ4 to 6. *PϽ0.05 vs no CRP in A and B, *PϽ0.05 vs basal in C. and the activation of SHIP-1 was completely inhibited in the presence of PP2 ( Figure 5C ). Thus, mirroring the events prompted by CRP, in endothelial cells aggregated IgG activates Src, leading to Fc␥RIIB activation and SHIP-1 activation.
CRP, Re-Endothelialization and Fc␥R
To determine the role of Fc␥RI in CRP actions on endothelium in vivo, mice null for the FcR␥-chain (FcR␥ Ϫ/Ϫ ), which contains the immunoreceptor tyrosine-based activation motif domain of Fc␥RI, were crossed with TG-CRP mice and the resulting progeny were crossed. Carotid artery re-endothelialization was then evaluated in the four following groups of littermates: FcR␥ ϩ/ϩ , FcR␥ ϩ/ϩ ; TG-CRP, FcR␥ Ϫ/Ϫ , and FcR␥ Ϫ/Ϫ ; TG-CRP. Compared with FcR␥ ϩ/ϩ controls, re-endothelialization was impaired in FcR␥ ϩ/ϩ ; TG-CRP mice ( Figure 6A ), as indicated by the larger area of remaining denudation that incorporated Evans blue dye in the latter group. Cumulative studies revealed that the area of remaining denudation was 4.0-fold greater in FcR␥ ϩ/ϩ ; TG-CRP versus FcR␥ ϩ/ϩ mice ( Figure 6B ). In contrast, despite having elevated CRP, FcR␥ Ϫ/Ϫ ; TG-CRP mice had normal re-endothelialization ( Figure 6A, B) .
To determine if partnership between Fc␥RI and Fc␥RIIB is required for CRP actions on endothelium in vivo, additional re-endothelialization experiments were performed in the following four groups of littermates: Fc␥RIIB ϩ/ϩ , Fc␥RIIB ϩ/ϩ ; TG-CRP, Fc␥RIIB Ϫ/Ϫ , and Fc␥RIIB Ϫ/Ϫ ; TG-CRP. Compared with Fc␥RIIB ϩ/ϩ controls, re-endothelialization was impaired in Fc␥RIIB ϩ/ϩ ; TG-CRP mice ( Figure 7A, B) , with the area of remaining denudation increased 3.4-fold in the latter group. In contrast, although CRP was similarly elevated in Fc␥RIIB Ϫ/Ϫ ; TG-CRP mice, they had normal re-endothelialization ( Figure 7A, B) . These collective observations, which mirror the findings for Fc receptor coupling in the actions of CRP on cultured endothelial cells, indicate that both the ␥-chain of Fc␥RI and Fc␥RIIB are required for CRP antagonism of re-endothelialization in vivo.
Discussion
CRP levels are strongly correlated with increased risk for cardiovascular disease and with endothelial dysfunction related to decreased NO bioavailability. 1,3,20 -22 We previously demonstrated that CRP potently antagonizes eNOS activation by diverse agonists at levels of CRP that have been associated with increased risk of cardiovascular disease, 23 and that the inhibitory Fc receptor Fc␥RIIB is critically involved in this process. 4 This represents a potentially major mechanism by which vascular NO bioavailability may be diminished under numerous disease conditions. Here, we show that the activating Fc Receptor, Fc␥RI, and functional coupling of Fc␥RI to Fc␥RIIB are required for CRP inhibition of eNOS in endothelial cells, thereby identifying another key cell surface receptor that participates in the negative regulation of NO production by the endothelium. We further show that, consistent with these observations in cell culture, both Fc␥RI and Fc␥RIIB are required for CRP to blunt endothelial repair in SHIP-1) activation. A, Bovine aortic endothelial cells (BAECs) were transfected with cDNA encoding human Fc␥RIIB and 48 hours later treated with CRP (100 g/mL, 15 minutes) in the presence of vehicle control (DMSO) or PP2 (10 mol/L). Cell lysates were immunoblotted with antiphospho-Fc␥RIIB (Tyr292) antibody and anti-Fc␥RIIB antibody. Summary data for ratio of P-Fc␥RIIB to total Fc␥RIIB is normalized to basal conditions. B, BAECs were treated with CRP (25 g/mL, 30 minutes) in the absence or presence of PP2, and cell lysates were immunoblotted with antiphospho-SHIP-1 (Tyr1020) and anti-SHIP-1 antibodies. Summary data for ratio of P-SHIP-1 to total SHIP-1 is normalized to basal conditions. In (A) and (B) , values are meanϮSEM, nϭ9. *PϽ0.05 vs no CRP. †PϽ0.05 vs no PP2.
vivo, which is related to a diminution in bioavailable NO. 5 Elucidation of these processes mediated by the Fc␥RI-Fc␥RIIB tandem provides further evidence that CRP is likely a causal factor in certain forms of cardiovascular disease, and is not merely a marker of chronic low-grade inflammation. In addition, because CRP impairs insulin signaling to eNOS in endothelial cells, 10 which normally promotes blood flow that augments glucose disposal in skeletal muscle, 24 these newly identified mechanisms are also potentially relevant to the insulin resistance that accompanies chronic inflammatory conditions, including obesity.
We further demonstrate that Src kinase is critically involved in the coupling of Fc␥RI to Fc␥RIIB in endothelial cells. In immune response cells in which Fc receptors serve their classical functions, Syk is the kinase that primarily links the activating phosphorylation of the immunoreceptor tyrosine-based activation motif within the ␥ subunit of Fc␥RI to the activating phosphorylation of the ITIM in Fc␥RIIB. 25, 26 Interestingly, whereas we now show that in response to CRP Src activation leads to eNOS antagonism, the stimulation of eNOS by numerous agonists including high-density lipoprotein, estrogen, and Summary data for pFc␥RIIB to total Fc␥RIIB ratio is normalized to basal conditions. C, BAECs were treated with aIgG (100 g/mL) for 30 minutes in the absence or presence of PP2, and cell lysates were immunoblotted with antiphospho-SHIP-1 (Tyr1020) and anti-SHIP-1 antibodies. Summary data for ratio of pSHIP-1 to total SHIP-1 is normalized to basal conditions. B and C, Values are meanϮSEM, nϭ9. *PϽ0.05 vs basal. †PϽ0.05 vs no PP2.
shear stress also entails Src activation, which precedes PI3 kinase and Akt activation that promotes eNOS Ser1177 phosphorylation. 16, 27, 28 These disparate roles of Src may be explained by the participation of different Src family members. Alternatively, because Src activation entails poorly understood mechanisms that involve plasma membrane receptor clustering and Src interacts with a number of receptors, 29 these disparate functions for Src may be explained by different responses by Src to Fc␥RI-Fc␥RIIB clustering versus eNOS-activating receptor clustering, or differences in the mode of physical linkage between Src and Fc receptors versus eNOS-activating receptors. 30 Having demonstrated an inhibitory role for Src in the regulation of eNOS for the first time, additional studies are now warranted to distinguish between these possibilities.
Recognizing that the classical ligand for Fc receptors is IgG, we previously demonstrated that heat-aggregated IgG mimicking immune complex causes eNOS antagonism to a degree that is comparable to that attained by CRP. 4 We now show that similar to CRP, the actions of aggregated IgG on eNOS are mediated by Src activation causing Fc␥RIIB ITIM phosphorylation and resulting activation of SHIP-1. Recognizing how eNOS contributes to insulinmediated glucose disposal, 24 these mechanisms may participate in the pathogenesis of not only the cardiovascular disease but also the insulin resistance that frequently complicate immune complex-mediated diseases such as rheumatoid arthritis or systemic lupus erythematosis. 31, 32 From a therapeutic perspective, the identification of Fc␥RI as the initiator of CRP action in endothelial cells provides a new cell surface target for potential interventions. Studies in humans and in mice indicate that attenuated function of Fc␥RIIB likely contributes to the pathogenesis of systemic lupus erythematosis. 33 Therefore, seeking to normalize CRP-related endothelial dysfunction by decreasing Fc␥RIIB activity, which can be accomplished by selective antibody-mediated blockade, 34 has the risk of promoting autoimmune disease. Alternatively, strategies that selectively prevent Fc␥RI activation now can be considered to blunt CRP-induced endothelial dysfunction without shifting the balance of activating and inhibitory Fc receptor activity toward excessive immune function. Now having greater evidence of an important role for SHIP-1 in eNOS antagonism by both CRP and immune complex, the phosphatase also may warrant consideration as a therapeutic target in endothelial cells. Although there is clear evidence of a causal role for CRP in hypertension and endothelial dysfunction in mice, 6, 35, 36 CRP has not yet been implicated as a contributing factor in the pathogenesis of such disorders in humans. However, now knowing that Fc␥RI and Fc␥RIIB are both important participants in CRP signaling in endothelium, it becomes apparent that there are multiple modifiers of CRP actions of relevance to vascular health. There are numerous polymorphisms in Fc receptors, some have known impact on receptor function, and there is also great variability in Fc receptor gene copy number. 37 Thus, as we continue to identify the participating signaling molecules, genetic and molecular modifiers of CRP action should be considered in our assessment of the role of CRP in cardiovascular disease pathogenesis and our use of CRP as a risk factor in patient populations.
